NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Neutral’ Rating on FibroGen, Inc. (NASDAQ: FGEN)
Mizuho Securities USA LLC has initiated coverage with a ‘Neutral’ rating and price target of $61 on shares of FibroGen, Inc.’s (NASDAQ: FGEN) stock. Roxadustat is the company’s most advanced product candidate, currently in phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD). The analyst noted that the global collaboration deals FibroGen has in place position the company for a successful, global commercial launch of roxadustat upon NDA approval. Additionally, the analyst believes the company is nearing full valuation. For more information, visit www.fibrogen.com About FibroGen, Inc. FibroGen, Inc., headquartered in San Francisco, CA with…







